Pure Global
NCT05279846

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

A Multi-center, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
Moberg Pharma AB·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Onychomycosis
Drug/Device/Intervention
MOB015B
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Moberg Pharma AB
Location
Multiple Locations,Multiple Locations,Multiple Locations, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
May 09, 2022
End date
Mar 01, 2024
Enrollment
350 participants
Primary outcome

Proportion of subjects with complete cure of the target toenail,Incidence of adverse events (Safety)

Summary

This is a Phase 3 multicenter, double blind study to evaluate the safety and efficacy of
 vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)

ICD-10 classifications
OnychogryphosisChromomycosis, unspecifiedOnycholysisActinomycosisBlastomycosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05279846
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05279846 through Pure Global AI's free database. This Phase 3 trial is sponsored by Moberg Pharma AB and is currently Recruiting. The study focuses on Onychomycosis. Target enrollment is 350 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.